Putative oncomodulin-2 (OCM2)

"Oncomodulin-2" (OCM2) is annotated in some protein and gene databases as a putative member of the EF-hand calcium-binding protein family, most closely related to β-parvalbumins such as oncomodulin (OCM/Parvalbumin β)[1][2][4]. However, there is **no published functional characterization or biomedical literature establishing oncomodulin-2 as a distinct molecular entity in humans**, and it is generally not recognized as a therapeutic target. Most peer-reviewed research and review articles on oncomodulin refer to the well-characterized "oncomodulin" (gene OCM), not "oncomodulin-2" (gene OCM2), and use the abbreviations "OCM" or "Ocm" exclusively for that protein[1][2][3]. The available database entries for "oncomodulin-2" are predicted proteins based on sequence homology, with no validated function, expression, or disease association in humans[4]. Accordingly, OCM2 should *not* be considered a validated drug target, biomarker, or subject of translational or clinical research.\n\n**Key points:**\n- There is **no evidence that OCM2 exists or functions as a separate, biologically relevant protein in humans**[1][2][4].\n- All major literature and functional studies refer only to “oncomodulin” (OCM), not to “oncomodulin-2” or “OCM2”[1][2][3].\n- Therefore, “oncomodulin-2” should be considered **incorrect as a biomedical target** under the guidelines provided.\n\nIf you are seeking information about the **functionally characterized EF-hand calcium-binding protein found in hair cells, immune cells, and cancer—the correct target is “oncomodulin” (gene name OCM), not “oncomodulin-2”/OCM2[1][2][3].

Other names

Oncomodulin-2OCM2OCMNOCMOMputative oncomodulin-2parvalbumin beta